<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1099</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10360354</PubmedId>
            <Abstract>The structure of a complex of influenza hemagglutinin (HA) with a neutralizing antibody shows that the antibody binds to HA at a distance from the virus receptor binding site. Comparison of the properties of this antibody and its Fab with those of an antibody that recognizes an epitope overlapping the receptor binding site leads to two main conclusions. First, inhibition of receptor binding is an important component of neutralization. Second, the efficiency of neutralization by the antibodies ranks in the same order as their avidities for HA, and their large size makes these antibodies highly efficient at neutralization, regardless of the location of their epitope in relation to the virus receptor binding site. These observations provide rationales for the range of antibody specificities that are detected in immune sera and for the distribution of sequence changes on the membrane-distal surface of influenza HAs that occur during 'antigenic drift.'</Abstract>
            <ArticleYear>1999</ArticleYear>
            <ArticlePages>530-4</ArticlePages>
            <ArticleTitle>A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Fleury</LastName>
                    <ForeName>D</ForeName>
                </Author>
                <Author>
                    <LastName>Barrère</LastName>
                    <ForeName>B</ForeName>
                </Author>
                <Author>
                    <LastName>Bizebard</LastName>
                    <ForeName>T</ForeName>
                </Author>
                <Author>
                    <LastName>Daniels</LastName>
                    <ForeName>R S</ForeName>
                </Author>
                <Author>
                    <LastName>Skehel</LastName>
                    <ForeName>J J</ForeName>
                </Author>
                <Author>
                    <LastName>Knossow</LastName>
                    <ForeName>M</ForeName>
                </Author>
            </Authors>
            <Affiliations>Laboratoire d'Enzymologie et Biochimie Structurales, UPR 9063, CNRS, Gif-sur-Yvette, France.</Affiliations>
            <ArticleChemicalList>Antibodies, Viral;Epitopes;Hemagglutinin Glycoproteins, Influenza Virus;Immunoglobulin Fab Fragments;Immunoglobulin G;Receptors, Virus</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Viral(chemistry; immunology); Antibody Affinity; Antibody Specificity; Binding Sites; Cell Line; Crystallization; Crystallography, X-Ray; Dogs; Epitopes(immunology); Hemagglutinin Glycoproteins, Influenza Virus(chemistry; immunology; metabolism); Immunoglobulin Fab Fragments(chemistry; immunology); Immunoglobulin G(chemistry; immunology); Models, Molecular; Molecular Sequence Data; Molecular Weight; Neutralization Tests; Orthomyxoviridae(growth &amp; development; immunology; metabolism; pathogenicity); Protein Conformation; Receptors, Virus(metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>6</Volume>
                <Issue>6</Issue>
                <Title>Nature structural biology</Title>
                <Issn>1072-8368</Issn>
                <MedlineTa>Nat Struct Biol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>HC45 Fab of influenza hemagglutinin</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>G65, K66, L75, D76, I78, D79, P90, H91, V94, F95, R106, K108, F110, P159, D287, P289, I290, D291</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>P03437.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>132504</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <EpitopeId>77323</EpitopeId>
                <ReferenceRegion>G49, K50, L59, D60, I62, D63, P74, H75, V78, F79, R90, K92, F94, P143, D271, P273, I274, D275</ReferenceRegion>
                <EpitopeEvidenceCode>Exact match to reference information</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The paper does not provide all residues for the epitope, it says that epitope comprises 17 residues, all at the base of the eight-stranded anti-parallel β-sheet structure that forms the membrane-distal domain of HA, 12 residues are in the four polypeptide stretches of HA1 chain (residues 59-63, 78-79, 90-94, 271-273 as in the mature chain). Here the epitope residues (18 residues) are curated as provided in the other paper of the authors [PMID: 10899782]. Epitope is located on HA1 chain and does not include any of the residues of the receptor binding site.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>1005672</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized I.P. with 8,000 HA units of purified influenza A (X31). Mice then received a booster injection week 8 containing 32,000 HA units of virus. Spleens were harvested and cells were fused with SP2/0-Ag 14 myeloma cells. Antibody was purified by affinity chromatography on protein A sepharose. The procedure is from [PMID: 6689229].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>436</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.8</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>HC45</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>HC45</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>CAC80067.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1QFU_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Bromelain released HA (BHA)</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQSSSTGKICNNPHRILDGIDCTLIDALLGDPHCDVFQNETWDLFVERSKAFSNCYPYDVPDYASLRSLVASSGTLEFITEGFTWTGVTQNGGSNACKRGPGSGFFSRLNWLTKSGSTYPVLNVTMPNNDNFDKLYIWGIHHPSTNQEQTSLYVQASGRVTVSTRRSQQTIIPNIGSRPWVRGLSSRISIYWTIVKPGDVLVINSNGNLIAPRGYFKMRTGKSSIMRSDAPIDTCISECITPNGSIPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGLFGAIAGFIENGWEGMIDGWYGFRHQNSEGTGQAADLKSTQAAIDQINGKLNRVIEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENAEEMGNGCFKIYHKCDNACIESIRNGTYDHDVYRDEALNNRFQIKGVELKSG</LinearSequence>
                                        <StartingPosition>17</StartingPosition>
                                        <EndingPosition>526</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03437.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>132504</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1QFU</ComplexPdbId>
                            <AntibodyChain1PdbChain>H</AntibodyChain1PdbChain>
                            <AntibodyChain2PdbChain>L</AntibodyChain2PdbChain>
                            <AntigenChainPdbChain>A</AntigenChainPdbChain>
                            <ViewerFlag>Y</ViewerFlag>
                            <Comments>Antigen and receptor binding residues are curated as provided in the paper of Flery et al., 2000 [PMID: 10899782]. Details of antigen-antibody contacts are not provided in the paper. There is no change in the overall X31 HA structure  upon complex formation as compared to the uncomplexed HA molecule [PDB: 1HGF]. However, there are significant local changes in HA such as movements of antigen residues A: D63, K92.</Comments>
                            <CuratedContacts>
                                <EpitopeResidues>A: G49, K50, L59, D60, I62, D63, P74, H75, V78, F79, R90, K92, F94, P143, D271, P273, I274, D275;</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: Q1:FR, V2:FR,  Y27:H1, T28:H1, T31:H1, Y32:H1, Y53:H2, R94:FR, L96:H3, T100A:H3, I100B:H3, I100C:H3; L: Y49:L2, S56:L2, E81:FR;</AntibodyResiduesInteractingWithAntigen>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResidues>A: T48, G49, K50, L59, D60, I62, D63, P74, H75, V78, F79, R90, K92, F94, P143, D271, A272, P273, I274</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: Q1, V2, G26, Y27, T28, T30, T31, Y32, Y53, D54, R94, L96, T99, I100B, T100A, I100C; L: Y49, S56, E81</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>900.1</ContactAreaForAntigen>
                                <ContactAreaForAntibody>936.1</ContactAreaForAntibody>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>1006415</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized I.P. with 8,000 HA units of purified influenza A (X31). Mice then received a booster injection week 8 containing 32,000 HA units of virus. Spleens were harvested and cells were fused with SP2/0-Ag 14 myeloma cells. Antibody was purified by affinity chromatography on protein A sepharose. Proc4edure is from Wrigley NG et al. Virol 1983;131:308-314.[PMID 6689229].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>18.0</QuantitativeMeasurement>
                            <AssayComments>Virus neutralization (N&lt;sub&gt;100&lt;/sub&gt;) was 18 (+/-2) nM.  The functional capacity of the Fab fragment of HC45 was approximately 1,000 times higher than the whole antibody, respectively.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>HC45</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>HC45</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>CAC80067.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1QFU_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P03437.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>132504</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>1006002</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized I.P. with 8,000 HA units of purified influenza A (X31). Mice then received a booster injection week 8 containing 32,000 HA units of virus. Spleens were harvested and cells were fused with SP2/0-Ag 14 myeloma cells. Antibody was purified by affinity chromatography on protein A sepharose. Proc4edure is from Wrigley NG et al. Virol 1983;131:308-314.[PMID 6689229].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The avidity (A,&lt;sub&gt;50&lt;/sub&gt;, the concentration of HA on virus at which 50% of the  IgG or Fab remains unbound) of this antibody for HA on the virus was determined to be 100 (+/-20) pM.  The functional capacity of the Fab fragment of HC45  was approximately 10 times higher than the whole antibody, respectively.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>HC45</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>HC45</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>CAC80067.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1QFU_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>132504</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>1650255</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>BALB/c mice were immunized I.P. with 8,000 HA units of purified influenza A (X31). Mice then received a booster injection week 8 containing 32,000 HA units of virus. Spleens were harvested and cells were fused with SP2/0-Ag 14 myeloma cells. Antibody was purified by affinity chromatography on protein A sepharose. Proc4edure is from Wrigley NG et al. Virol 1983;131:308-314.[PMID 6689229].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>45</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>3.0</QuantitativeMeasurement>
                            <AssayComments>The relative affinities of whole antibody for the monovalent membrane distal domain of influenza A X31 HA was evaluted using BIAcore-SPR to establish the ratio of dissociation.  The dissociation value (K&lt;sub&gt;D&lt;/sub&gt;) of the mAb HC45 for monovalent HA was 3 (+/-1) nM. The functional capacity of the Fab fragment of HC45  was approximately 10 times higher than the whole antibody, respectively.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>HC45</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>HC45</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>CAC80067.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1QFU_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Membrane distal domain</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TITDDQIEVTNATELVQSSSTGKICNNPHRILDGIDCTLIDALLGDPHCDVFQNETWDLFVERSKAFSNCYPYDVPDYASLRSLVASSGTLEFITEGFTWTGVTQNGGSNACKRGPGSGFFSRLNWLTKSGSTYPVLNVTMPNNDNFDKLYIWGIHHPSTNQEQTSLYVQASGRVTVSTRRSQQTIIPNIGSRPWVRGLSSRISIYWTIVKPGDVLVINSNGNLIAPRGYFKMRTGKSSIMRSDAPIDTCISECITPNGSIPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQT</LinearSequence>
                                        <StartingPosition>44</StartingPosition>
                                        <EndingPosition>344</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03437.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>132504</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

